XBiotech
XBIT
36 hedge funds and large institutions have $4.56M invested in XBiotech in 2026 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 12 reducing their positions, and 3 closing their positions.
114% more call options, than puts
Call options by funds: $244K | Put options by funds: $114K
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
0.04% less ownership
Funds ownership: 6.54% → 6.5% (-0.04%)
3% less capital invested
Capital invested by funds: $4.68M → $4.56M (-$124K)
3% less funds holding
Funds holding: 37 → 36 (-1)
58% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$74.2K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$70.6K |
| 3 |
BlackRock
New York
|
+$67.8K |
| 4 |
Renaissance Technologies
New York
|
+$46.5K |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$36K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$118K |
| 2 |
Millennium Management
New York
|
-$63.4K |
| 3 |
Morgan Stanley
New York
|
-$42.8K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$40.9K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$31.2K |
XBIT Hedge Fund Activity: Q2 2026 in Review
36 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in XBiotech (XBIT) for Q2 2026, worth a combined $4.56M — down 2.7% from $4.68M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new XBIT positions and 3 closed out — a net gain of 1 holder — while 5 added to existing stakes and 12 trimmed.
The largest buyer was GSA Capital Partners, opening a new position worth an estimated $74.2K. The largest seller was Jane Street, cutting an estimated $118K.
- 36 institutional investors held XBiotech (XBIT) as of Q2 2026, down from 37 in Q1 2026.
- Funds reported $4.56M of XBiotech stock for Q2 2026, down 2.7% quarter-over-quarter.
- 4 funds opened new XBiotech positions in Q2 2026 and 3 closed out, a net change of +1 holder.
- The largest XBiotech buyer in Q2 2026 was GSA Capital Partners, an estimated $74.2K added.
- The largest XBiotech seller in Q2 2026 was Jane Street, an estimated $118K sold.
Based on aggregated 13F filings for Q2 2026.